Integumen Share Discussion Threads

[mulligut] 07/1/2019 08:08

Costs have to be down quite a lot as they disposed of TSPRO before year-end and saved £1.19m in ongoing liabilities and STOER is at break-even. Sales are up. Orders are up.

[dave4545] 07/1/2019 08:07

Promising start.

Cannot buy anything online and can sell for the offer price of 0.63p

[dave4545] 07/1/2019 08:00

74tom

So what if it's still loss making, given the growth in sales and potential of new
products it's the future that counts. Could easily swing from a small loss in 2018 to a healthy profit in 2019

[buywell3] 07/1/2019 07:58

Certainly a lot happening ... so news flow should be regular

Labskin AI and the integration of data analytics using the Labskin-On-A-Chip portable microbiology laboratory testing with results expected in early Q2 2019


So sales might start soon afterwards



Labskin additional laboratories at our HQ in York expected to be ready in February 2019


So bigger orders to come one would think

[74tom] 07/1/2019 07:56

Whilst the above is very harsh, given that we already knew revenues were increasing from a low base, I expected to see more detail on costs and year end cash position.

Revenue is a vanity metric without evidence of costs, and it makes me think that costs are still high which is why they haven’t been mentioned... Hopefully wrong here, but more transparency on costs is definitely needed in the next TU.

[mulligut] 07/1/2019 07:54

Morning all. I have updated the header on this thread. What a great update. New management has consistently said in trading updates what they would do and then went and did it. That alone makes a welcome change, considering some of the companies on AIM that have little or no potential. Seriously undervalued at these levels.

[buywell3] 07/1/2019 07:51

It will be interesting to see how this develops

''Labskin Cannabinoid (CBD) testing protocols prepared and will be offered to existing and new skin-care clients''

As well as the new Stoer offering

New formulation for STOER For Men, a skin care range of products owned by Integumen, is being tested with CBD oils.

CBD oil is an extract from the Cannabis Sativa plant. Cellulac (9.35% owned by Integumen) has developed a low-cost CBD oil extraction process and is collaborating with Labskin to provide a formulation for the STOER For Men range of cosmetics. Testing is underway using CBD oils of a quality comparable to that produced by Cellulac in an earlier proof of concept project. Results expected end of Q1 2019.

Things are now heading in the right direction .. it's down to GB to keep the momentum building up

Labskin sales are doing well thus far .... now it just needs scaling up

[dave4545] 07/1/2019 07:48

Give it a chance PUG

They can only do so much in a short space of time.

I'm very happy with that update

[pugugly] 07/1/2019 07:38

A lot of noise about not very much (imo) Still appears to be swallowing cash fast - If thsi was an animal one should have called the vet to put out of its misery - No indication in TU as to when will be cash flow positive -
Nice niche products but cannot see when the company will be commercially viable

[dave4545] 04/1/2019 14:28

Buy order perhaps.

It's dropped on some sales but now back up again on nothing.

Looks good anyway.

Onwards and upwards towards 1p

[mulligut] 04/1/2019 12:11

2019 is looking so much better in this share compared to the rest of the market. I guess everyone has skin and there are lots of products to be tested on both sides of the Atlantic, so not going to be affected by Brexit.

[dave4545] 03/1/2019 11:04

Lovely you cannot even buy 50,000 at 0.55p atm

Was overdue this though.

[dave4545] 03/1/2019 10:16

Took all the size out of the market along with the other buys.

Just tried a fill or kill at 0.52p for 250k and was rejected.

[dave4545] 03/1/2019 10:10

2 million delayed buy at 0.495p mid price showing as a sale but it's 100% a buy as last time I checked limits it was around mid price to buy

[cocker] 30/12/2018 23:10

Your post Dave surely should have read. New years resolution TO engage brain before posting.

[mulligut] 29/12/2018 12:18

To misquote Julius Caesar, or Hilary Clinton. He came. He saw and he is kicking ass.

[cocker] 29/12/2018 11:11

With comments like that, GJB might let you take a stake in the next placing Dave. After all you were a little dismayed that you weren't ask last time.

[dave4545] 28/12/2018 13:35

Post 417 a great read

[supertag] 27/12/2018 14:04

You too Gerry
Supertag

[buywell2] 20/12/2018 03:53

My six penneth

Of course what I post below is one version of the event/s that are unfolding, I would imagine both Integumen and Enhance Skin Products don't want to make lawyers even richer than they already are ... so .... as Trump would say ... negotiations are taking place ; I would have thought.


Clearly there is a seller out there at around 0.44p

How many SKIN shares they have ... we don't know

Is it Enhance Skin Products/Donald Nicholson ... we don't know

Perhaps an RNS will tell us soon

We have an overhang situation .... which for the brave might present an opportunity

It would be nice to know who was buying as well ... one would surmise that when the seller stops selling ( assuming just one ) ... then good news could get SKIN growing again and repair the share price damage of the past 12 months and more.





Enhance Skin Products Inc. Clarifies Integumen plc RNS statement

September 19, 2018

Enhance Skin Products Inc. (the “Company”;) notes a Regulatory News Service (“RNS”) announcement made by Integumen plc (“Integumen221;) on September 19, 2018, further to the Company’s own Press Release of August 18, 2018, and wishes to make the following clarifications;

Mercuriali Limited (“Mercuriali”) owns no shares in Integumen. The Company currently holds 29,488,144 fully paid ordinary shares of Integumen representing 11.19% of the issued and outstanding shares.

Neither Donald Nicholson, the Company’s President & CEO, or Mercuriali has made an offer, or intend to make an offer, to acquire the Integumen skincare assets. The Company and related parties, of which Mercuriali is one, has made various proposals to Integumen in respect of the settlement of obligations and defaults under the Asset Purchase Agreement (“APA”) as set out in the Company’s own announcement which may include the return of assets sold.

Integumen Plc has guaranteed the due and punctual performance, observance and discharge by Integumen Inc of all of Integumen Inc’s obligations under the APA.”

There can be no certainty that the Company will be successful in its claims against Integumen or that a settlement can be reached with Integumen.